Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, RECAP, an open-label extension study from CAPACITY, and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. The top-line efficacy, safety and tolerability data reported in this press release are from analyses of the highest areas of interest to the company based on the prior clinical experience with pirfenidone in IPF patients. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... WriteResult, a premier provider of ePRO technologies and ... of Public Health and New Haven Farms to capture ... project. The goal of the study was to evaluate ... access to fresh produce and nutrition education on food ... blood pressure, diabetes and weight gain. Patients completed an ...
(Date:3/25/2015)... 2015 The surging prevalence of ... fuelled social media growth, with over 50% of ... social networking. Insurance companies are making use of ... and promote a diversity of their services and ... exploiting social networking services as part of sales ...
(Date:3/25/2015)... London, UK (PRWEB) March 25, 2015 ... of natural ingredients in all forms of food nutrients, ... led to a substantial rise in demand for natural ... astaxanthin have started to ramp up their capacities to ... for both natural and synthetic source astaxanthin (used in ...
(Date:3/25/2015)... ST LOUIS and the HAGUE, ... publication of two-year results of LES Stimulation therapy for ... of the journal Surgery [ Surgery ... and efficacy of its minimally-invasive therapy. ... an average duration of 11 years and taking prescribed ...
Breaking Biology Technology:Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 3Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 3
... With dimensions measuring billionths of a meter, nanoparticles are way ... is becoming possible for today,s scientists not only to see ... are arranged in three dimensions using a technique called nanocrystallography. ... as x-ray synchrotrons, are only available at a handful of ...
... 4, 2012  Andrew Technologies, LLC launched the HydraSolve™ ... Aesthetic Plastic Surgery (ASAPS) in Vancouver, BC. ASAPS ... surgeons focused on aesthetic body contouring and is ... (Photo: http://photos.prnewswire.com/prnh/20120504/NY98979 ) ...
...  The San Diego Chapter of the National Investor Relations ... Tips & Tactics for Establishing & Maintaining a Successful ... 2012 meeting. The panel of seasoned IR ... and share their unique perspectives on what makes an ...
Cached Biology Technology:New technique uses electrons to map nanoparticle atomic structures 2New technique uses electrons to map nanoparticle atomic structures 3New HydraSolve™ Lipoplasty System launched at American Society of Aesthetic Plastic Surgery Meeting 2New HydraSolve™ Lipoplasty System launched at American Society of Aesthetic Plastic Surgery Meeting 3New HydraSolve™ Lipoplasty System launched at American Society of Aesthetic Plastic Surgery Meeting 4NIRI San Diego May Meeting: Seasoned IROs Discuss "Tips & Tactics for Establishing and Maintaining A Successful Investor Relations Program" 2NIRI San Diego May Meeting: Seasoned IROs Discuss "Tips & Tactics for Establishing and Maintaining A Successful Investor Relations Program" 3
(Date:3/17/2015)... , March 17, 2015 Emotient, ... analytics software, today announced general availability of ... service for the analysis of facial expressions. The ... advertising, media content, products and services. It delivers ... engagement and sentiment - as derived from facial ...
(Date:3/16/2015)... Between 16 and 20 ... innovations in biometric identification at the CeBIT exhibition ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) , ... at the forefront: the company,s all new BiometricGate ... Germany . BiometricGate is the first ...
(Date:3/12/2015)... -- The mascots of the Atlantic Coast Conference spent ... Forest Baptist Medical Center. They stopped by as part ... Basketball Tournament. Young patients enjoyed bonding with their favorite ... Brenner Children,s Hospital is the pediatric arm ... hospital in northwest North Carolina ...
Breaking Biology News(10 mins):New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... (PINK SHEETS: DLSC) announces the appointment of Randall ... McCormick replaces outgoing President Mr. Berge Heede who resigned for personal ... "resigning for personal reasons and to allow Mr. McCormick to take ... the current Treasurer, will maintain that responsibility as well. , ...
... Legal loopholes and insufficient law enforcement mean that ... market in Asia, says a new report from ... report also raises concerns that legal provisions governing ... illegal trade in wild-caught, highly-endangered Asian elephants from ...
... It,s common knowledge that a protective navy of ... least temporarily disturb the normal balance. But it,s unclear ... full array of "good bacteria" return promptly or remain ... mice, University of Michigan scientists have shown for the ...
Cached Biology News:delSECUR CORPORATION Announces Appointment of the Company's President & CEO 2Elephant-size loopholes sustain Thai ivory trade 2Antibiotics take toll on beneficial microbes in gut 2Antibiotics take toll on beneficial microbes in gut 3
... whose sequence corresponds to residues 1-18 from rat rab 3D. ... - A - S - A - S - E - ... - D - A - A - D - Q - ... control experiments with the polyclonal antibody that reacts with this product ...
Rabbit polyclonal antibody to Glutathione-S-Transferase (GST)...
... Assay Kit contains all reagents necessary to ... lineage, as determined by staining for mineralization. ... necessary reagents and a protocol for quantifying ... product is useful for studying the effects ...
... discovery races ever faster, you need a partner ... So our constant focus is on providing tools ... why our Biomek 3000 Laboratory Automation Workstation offers ... it is flexible. By integrating all aspects of ...
Biology Products: